- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04903899
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)
A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
The LuDO-N Trial is a multi-centre phase II clinical trial on 177Lu-DOTATATE treatment of recurrent or relapsed high-risk neuroblastoma in children. The LuDO-N Trial builds on the experience from the previous LuDO Trial and utilises an intensified dosing schedule to deliver 2 doses over a 2-week period, in order to achieve a maximal effect on the often rapidly progressing disease. This strategy requires a readiness for autologous stem cell transplantation in all patients, but is not anticipated to increase the risk of long-term sequelae, since the cumulative radiation dose remains unchanged. The primary aim of the study is to assess the response to 177Lu-DOTATATE treatment at 1 and 4 months after end of treatment. Secondary aims are to assess survival and treatment-related toxicity. Additional aim are to correlate tumour dosimetry with response, correlate SSTR-2 expression with 68Ga-DOTATATE uptake and to correlate the uptake with the treatment response.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jakob Stenman, MD PhD
- Phone Number: 46 (0)51770000
- Email: jakob.stenman@regionstockholm.se
Study Contact Backup
- Name: Kleopatra Georgantzi, MD
- Phone Number: 46 (0)51770000
- Email: kleopatra.georgantzi@regionstockholm.se
Study Locations
-
-
Copenhagen
-
Copenhagen, Copenhagen, Denmark, DK-2100
- Recruiting
- Rigshospitalet
-
Contact:
- Jesper S Brok, MD PhD
- Email: jesper.sune.brok@regionh.dk
-
Principal Investigator:
- Jesper S Brok, MD PhD
-
-
-
-
Vilnius County
-
Vilnius, Vilnius County, Lithuania, LT-08406
- Recruiting
- Vilnius University Hospital
-
Contact:
- Jelena Rascon, MD PhD
- Email: jelena.rascon@gmail.com
-
Principal Investigator:
- Jelena Rascon, MD PhD
-
-
-
-
Utrecht
-
Utrecht, Utrecht, Netherlands, NL-3584
- Recruiting
- Princess Maxima Center for Pediatric Oncology
-
Contact:
- Max M van Noesel, MD PhD
- Email: M.M.vanNoesel@prinsesmaximacentrum.nl
-
Principal Investigator:
- Max M van Noesel, MD PhD
-
-
-
-
Oslo
-
Oslo, Oslo, Norway, NO-0372
- Recruiting
- Oslo University Hospital, Rikshospitalet
-
Contact:
- Kirsten Brunsvig Jarvis, MD
- Email: kirjar@ous-hf.no
-
Principal Investigator:
- Kirsten Brunsvig Jarvis, MD
-
-
-
-
-
Barcelona, Spain
- Recruiting
- Pediatric Cancer Center Barcelona, Sant Joan de Déu Barcelona Children's Hospital
-
Contact:
- Maite Gorostegui Obanos, MD
- Phone Number: +34 93 280 40 00
- Email: maite.gorostegui@sjd.es
-
Principal Investigator:
- Maite Gorostegui Obanos, MD
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Sweden, SE-171 76
- Recruiting
- Karolinska University Hospital
-
Principal Investigator:
- Kleopatra Georgantzi, MD
-
Contact:
- Kleopatra Georgantzi, MD
- Email: kleopatra.georgantzi@regionstockholm.se
-
Contact:
- Jakob Stenman, MD PhD
- Email: jakob.stenman@regionstockholm.se
-
-
-
-
-
Glasgow, United Kingdom, G51 4TF
- Recruiting
- GREATER GLASGOW HEALTH BOARD, Royal Hospital for Children
-
Contact:
- Diana Mcintosh, Consultant Paediatric Oncologi
- Email: Diana.Mcintosh2@nhs.scot
-
Principal Investigator:
- Diana Mcintosh, MD
-
London, United Kingdom, NW1 2PG
- Recruiting
- University College London Hospitals NHS FOUNDATION TRUST
-
Contact:
- Jenny Gains, Consultant in Clinical Oncolog
- Phone Number: +44-203 447 4437
- Email: jenny.gains@nhs.net
-
Principal Investigator:
- Jenny Gains, MD
-
London, United Kingdom, SW3 6JJ
- Recruiting
- The Royal Marsden NHS Foundation Trust of Fulham Road
-
Contact:
- Sucheta Vaidya, Paediatric Oncologist
- Email: Sucheta.Vaidya@rmh.nhs.uk
-
Principal Investigator:
- Sucheta Vaidya, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathology 1.1. Histologically confirmed diagnosis of neuroblastoma 1.2. Immunohistochemical staining for somatostatin receptors (SSTR) performed from primary tumor tissue when available
- Relapsed or primary refractory high-risk neuroblastoma: INSS stage 4 disease or INRGSS stage M disease
- Age >18 months at the time of enrolment into this study
- Life expectancy of greater than 3 months
- Performance Status 5.1. Karnofsky > 50% (for patients > 12 years of age) 5.2. Lansky > 50% (for patients ≤ 12 years of age)
- Prior treatment 6.1. Two-week washout from any prior treatment 6.2. Patients must have recovery of hematological toxicity following previous therapy 6.3. Adequate recovery from major surgery prior to receiving study treatment
- Diagnostic imaging 7.1. Uptake in the primary tumor or metastatic tumour deposits on 68Ga-DOTATATE PET/CT at least higher than the liver uptake and performed within two months prior to registration 7.2. 123I-mIBG scintigraphy to be performed within two months prior to registration 7.3. CT or MRI of the primary tumor and bulky metastatic sites within two months prior to registration
- Laboratory requirements to be performed within 7 days prior to commencing trial treatment 8.1. Hematology: 8.1.1. Hemoglobin, If Hb is <120 g/L then patient will receive a blood transfusion prior to commencing trial treatment 8.1.2. Absolute neutrophil count > 1.0 x 109/L 8.1.3. Absolute Platelets > 50 x 109/L 8.2. Biochemistry: 8.2.1. Bilirubin within 1.5 x ULN 8.2.2. ALT within 2.5 x ULN 8.2.3. AST within 2.5 x ULN 8.2.4. GGT within 5 x ULN 8.2.5. ALP within 5 x ULN 8.2.6. Glomerular filtration rate >50mL/min/1.73m2 assessed by a recognised method, such as inulin, 51Cr-EDTA, 99mTc-DTPA or iohexol clearance and performed within 2 months prior to registration 8.2.7. Urinary catecholamine metabolites measured within 2 months prior to registration
- Peripheral blood stem cells (PBSC) 9.1. A minimum of 2 x106 CD34+ cells/kg (optimally 6 x106 CD34+ cells/kg) must be available for each study subject prior to registration
- Written informed consent from patient and/or parent(s) or legal guardian(s) in accordance with national regulations, prior to registration or any trial-related screening procedures
Exclusion Criteria:
- Not fit enough to undergo proposed study treatment, as assessed by national PI, considering precautions defined in the latest version of the 177Lutetium-DOTATATE SmPC.
- Pregnant or lactating patient
- Concurrent treatment with any anti-tumor agents
- Prior treatment with other radiolabeled somatostatin analogues
- Hypersensitivity to any component of the investigational drug 177Lutetium-DOTATATE
- Treatment with long-acting somatostatin analogues within 30 days, or with short-acting somatostatin analogues within 24 hours prior the administration of 177Lutetium-DOTATATE
- Hydronephrosis in either kidney on baseline MRI or CT; patients can still be eligible for inclusion if urinary tract obstruction can be ruled out by renography
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 177Lu-DOTATATE
A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks. |
A total of two doses of 177Lu-DOTATATE will be administered intravenously. A weight-based activity of 400 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT/CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, to avoid renal toxicity. The aim is to deliver two doses of 177Lu-DOTATATE two weeks apart. The minimum time between treatments is 2 weeks. The maximum time between treatments is 4 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response by the Revised International Neuroblastoma Response Criteria (INRC) at 1 month after the completion of therapy
Time Frame: 1 months following end of treatment
|
Treatment response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC) |
1 months following end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response based on 68Ga-DOTATOC PET/CT imaging at 1 and 4 months after completion of therapy in measurable target lesions
Time Frame: 1 and 4 months following end of treatment
|
Response based on 68Ga-DOTATOC PET/CT imaging after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response based on 123I-mIBG SPECT/CT imaging (when available) at 1 and 4 months after completion of therapy in measurable target lesions
Time Frame: 1 and 4 months following end of treatment
|
Response based on 123I-mIBG SPECT/CT imaging (when available) after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response by the Revised INRC criteria at 4 months after the completion of therapy
Time Frame: 4 months following end of treatment
|
Response by the Revised INRC criteria |
4 months following end of treatment
|
|
Progression-free survival
Time Frame: Time from registration to progression or death, up to 5 years following end of treatment
|
Time to progress or death, whichever occurs first |
Time from registration to progression or death, up to 5 years following end of treatment
|
|
Overall survival - up to 5 years after End of Treatment
Time Frame: Time from registration to the the date of death, up to 5 years following end of treatment
|
Overall survival |
Time from registration to the the date of death, up to 5 years following end of treatment
|
|
Hematological and renal toxicity according to CTCAE 5.0
Time Frame: From first treatment dose until the date of first documented progression, assessed up to 60 months
|
Hematological and renal toxicity according to CTCAE 5.0 |
From first treatment dose until the date of first documented progression, assessed up to 60 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dosimetry (absorbed dose in Gy) in measurable target lesions and risk organs
Time Frame: At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
Measured by SPECT/CT |
At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology
Time Frame: Throughout the trial treatment phase (5 years)
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology |
Throughout the trial treatment phase (5 years)
|
|
The uptake on 68Gallium-DOTATOC PET/CT by SUVmax (maximum standardized uptake value) in measurable target lesions
Time Frame: At end of treatment, and 1 and 4 months after end of treatment.
|
Measured by SUVmax (maximum standardized uptake value) |
At end of treatment, and 1 and 4 months after end of treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jakob Stenman, MD PhD, Karolinska University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroectodermal Tumors, Primitive, Peripheral
- Neuroectodermal Tumors, Primitive
- Neuroblastoma
- lutetium Lu 177 dotatate
Other Study ID Numbers
- LuDO-N
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.